166 related articles for article (PubMed ID: 25885574)
1. A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
Kümler I; Balslev E; Stenvang J; Brünner N; Nielsen D
BMC Cancer; 2015 Feb; 15():78. PubMed ID: 25885574
[TBL] [Abstract][Full Text] [Related]
2. Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.
Kümler I; Balslev E; Stenvang J; Brünner N; Ejlertsen B; Jakobsen EH; Nielsen DL
BMC Cancer; 2019 Jun; 19(1):573. PubMed ID: 31196001
[TBL] [Abstract][Full Text] [Related]
3. DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
Nygård SB; Vainer B; Nielsen SL; Bosman F; Tejpar S; Roth A; Delorenzi M; Brünner N; Budinska E
Clin Cancer Res; 2016 Apr; 22(7):1621-31. PubMed ID: 26542057
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Jandu H; Aluzaite K; Fogh L; Thrane SW; Noer JB; Proszek J; Do KN; Hansen SN; Damsgaard B; Nielsen SL; Stougaard M; Knudsen BR; Moreira J; Hamerlik P; Gajjar M; Smid M; Martens J; Foekens J; Pommier Y; Brünner N; Schrohl AS; Stenvang J
BMC Cancer; 2016 Jan; 16():34. PubMed ID: 26801902
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.
Nygård SB; Christensen IJ; Nielsen SL; Nielsen HJ; Brünner N; Spindler KL
Scand J Gastroenterol; 2014 Jan; 49(1):84-91. PubMed ID: 24256029
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
Palshof JA; Høgdall EV; Poulsen TS; Linnemann D; Jensen BV; Pfeiffer P; Tarpgaard LS; Brünner N; Stenvang J; Yilmaz M; Nielsen DL
BMC Cancer; 2017 Jan; 17(1):48. PubMed ID: 28077117
[TBL] [Abstract][Full Text] [Related]
7. A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
Kümler I; Brünner N; Stenvang J; Balslev E; Nielsen DL
Breast Cancer Res Treat; 2013 Apr; 138(2):347-58. PubMed ID: 23512247
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer.
Kümler I; Balslev E; Poulsen TS; Nielsen SL; Nygård SB; Rømer MU; Christensen IJ; Høgdall E; Moreira J; Nielsen DL; Brünner N; Stenvang J
Int J Cancer; 2015 Oct; 137(8):2000-6. PubMed ID: 25855483
[TBL] [Abstract][Full Text] [Related]
9. A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.
Segar JM; Reed D; Stopeck A; Livingston RB; Chalasani P
Oncologist; 2019 Dec; 24(12):1512-e1267. PubMed ID: 31383812
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
Hayashi H; Tsurutani J; Satoh T; Masuda N; Okamoto W; Morinaga R; Terashima M; Miyazaki M; Okamoto I; Nishida Y; Tominaga S; Tokunaga Y; Yamaguchi M; Sakamoto J; Nakayama T; Nakagawa K
Breast Cancer; 2013 Apr; 20(2):131-6. PubMed ID: 22124996
[TBL] [Abstract][Full Text] [Related]
11. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Awada A; Garcia AA; Chan S; Jerusalem GH; Coleman RE; Huizing MT; Mehdi A; O'Reilly SM; Hamm JT; Barrett-Lee PJ; Cocquyt V; Sideras K; Young DE; Zhao C; Chia YL; Hoch U; Hannah AL; Perez EA;
Lancet Oncol; 2013 Nov; 14(12):1216-25. PubMed ID: 24095299
[TBL] [Abstract][Full Text] [Related]
12. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Licitra EJ; Vyas V; Nelson K; Musanti R; Beers S; Thomas C; Poplin E; Smith S; Lin Y; Schaaf LJ; Aisner J; Gounder M; Rajendra R; Saleem A; Toppmeyer D; Rubin EH
Clin Cancer Res; 2003 May; 9(5):1673-9. PubMed ID: 12738720
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Hochster HS; Uboha N; Messersmith W; Gold PJ; ONeil BH; Cohen D; Denlinger C; Cohen S; Leichman CG; Leichman L; Lenz HJ
Cancer Chemother Pharmacol; 2015 Jan; 75(1):17-23. PubMed ID: 25322874
[TBL] [Abstract][Full Text] [Related]
15. Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.
Amzerin M; Mokrim M; Errihani H; Piccart MJ
J Med Case Rep; 2015 Feb; 9():5. PubMed ID: 25971303
[TBL] [Abstract][Full Text] [Related]
16. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.
Rolle CE; Kanteti R; Surati M; Nandi S; Dhanasingh I; Yala S; Tretiakova M; Arif Q; Hembrough T; Brand TM; Wheeler DL; Husain AN; Vokes EE; Bharti A; Salgia R
Mol Cancer Ther; 2014 Mar; 13(3):576-84. PubMed ID: 24327519
[TBL] [Abstract][Full Text] [Related]
17. Rationale for mitomycin and irinotecan use in advanced breast cancer.
Xu Y; Shapiro CL
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):25-8. PubMed ID: 12800602
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
Mrozek E; Kolesar J; Young D; Allen J; Villalona-Calero M; Shapiro CL
Ann Oncol; 2008 Aug; 19(8):1417-1422. PubMed ID: 18407955
[TBL] [Abstract][Full Text] [Related]
19. TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity.
Rømer MU; Jensen NF; Nielsen SL; Müller S; Nielsen KV; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2012 Jan; 47(1):68-79. PubMed ID: 22171973
[TBL] [Abstract][Full Text] [Related]
20. [Retrospective study on utility of irinotecan hydrochloride in patients with advanced and recurrent breast cancer].
Okubo S; Kurebayashi J; Sonoo H; Hirono M; Nomura N; Udagawa K; Yamamoto Y; Ikeda M; Nakashima K; Tanaka K
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1441-5. PubMed ID: 14584275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
